298 related articles for article (PubMed ID: 22223645)
1. Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics.
Liu Q; Kirubakaran S; Hur W; Niepel M; Westover K; Thoreen CC; Wang J; Ni J; Patricelli MP; Vogel K; Riddle S; Waller DL; Traynor R; Sanda T; Zhao Z; Kang SA; Zhao J; Look AT; Sorger PK; Sabatini DM; Gray NS
J Biol Chem; 2012 Mar; 287(13):9742-9752. PubMed ID: 22223645
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR.
Liu Q; Xu C; Kirubakaran S; Zhang X; Hur W; Liu Y; Kwiatkowski NP; Wang J; Westover KD; Gao P; Ercan D; Niepel M; Thoreen CC; Kang SA; Patricelli MP; Wang Y; Tupper T; Altabef A; Kawamura H; Held KD; Chou DM; Elledge SJ; Janne PA; Wong KK; Sabatini DM; Gray NS
Cancer Res; 2013 Apr; 73(8):2574-86. PubMed ID: 23436801
[TBL] [Abstract][Full Text] [Related]
3. ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma.
Neil J; Shannon C; Mohan A; Laurent D; Murali R; Jhanwar-Uniyal M
Int J Oncol; 2016 Mar; 48(3):1045-52. PubMed ID: 26719046
[TBL] [Abstract][Full Text] [Related]
4. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.
Yu K; Toral-Barza L; Shi C; Zhang WG; Lucas J; Shor B; Kim J; Verheijen J; Curran K; Malwitz DJ; Cole DC; Ellingboe J; Ayral-Kaloustian S; Mansour TS; Gibbons JJ; Abraham RT; Nowak P; Zask A
Cancer Res; 2009 Aug; 69(15):6232-40. PubMed ID: 19584280
[TBL] [Abstract][Full Text] [Related]
5. Disentangling the signaling pathways of mTOR complexes, mTORC1 and mTORC2, as a therapeutic target in glioblastoma.
Jhanwar-Uniyal M; Dominguez JF; Mohan AL; Tobias ME; Gandhi CD
Adv Biol Regul; 2022 Jan; 83():100854. PubMed ID: 34996736
[TBL] [Abstract][Full Text] [Related]
6. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.
Feldman ME; Apsel B; Uotila A; Loewith R; Knight ZA; Ruggero D; Shokat KM
PLoS Biol; 2009 Feb; 7(2):e38. PubMed ID: 19209957
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell lymphoma (CTCL) cells.
Marzec M; Liu X; Wysocka M; Rook AH; Odum N; Wasik MA
PLoS One; 2011; 6(9):e24849. PubMed ID: 21949767
[TBL] [Abstract][Full Text] [Related]
8. Rapamycin-resistant mTORC1 kinase activity is required for herpesvirus replication.
Moorman NJ; Shenk T
J Virol; 2010 May; 84(10):5260-9. PubMed ID: 20181700
[TBL] [Abstract][Full Text] [Related]
9. Ataxia telangiectasia mutated impacts insulin-like growth factor 1 signalling in skeletal muscle.
Ching JK; Luebbert SH; Collins RL; Zhang Z; Marupudi N; Banerjee S; Hurd RD; Ralston L; Fisher JS
Exp Physiol; 2013 Feb; 98(2):526-35. PubMed ID: 22941977
[TBL] [Abstract][Full Text] [Related]
10. Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin.
Bhagwat SV; Gokhale PC; Crew AP; Cooke A; Yao Y; Mantis C; Kahler J; Workman J; Bittner M; Dudkin L; Epstein DM; Gibson NW; Wild R; Arnold LD; Houghton PJ; Pachter JA
Mol Cancer Ther; 2011 Aug; 10(8):1394-406. PubMed ID: 21673091
[TBL] [Abstract][Full Text] [Related]
11. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
[TBL] [Abstract][Full Text] [Related]
12. Combination of mTOR and EGFR kinase inhibitors blocks mTORC1 and mTORC2 kinase activity and suppresses the progression of colorectal carcinoma.
Wang Q; Wei F; Li C; Lv G; Wang G; Liu T; Bellail AC; Hao C
PLoS One; 2013; 8(8):e73175. PubMed ID: 23991179
[TBL] [Abstract][Full Text] [Related]
13. Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas.
Shortt J; Martin BP; Newbold A; Hannan KM; Devlin JR; Baker AJ; Ralli R; Cullinane C; Schmitt CA; Reimann M; Hall MN; Wall M; Hannan RD; Pearson RB; McArthur GA; Johnstone RW
Blood; 2013 Apr; 121(15):2964-74. PubMed ID: 23403624
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer.
Liu Q; Chang JW; Wang J; Kang SA; Thoreen CC; Markhard A; Hur W; Zhang J; Sim T; Sabatini DM; Gray NS
J Med Chem; 2010 Oct; 53(19):7146-55. PubMed ID: 20860370
[TBL] [Abstract][Full Text] [Related]
15. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1.
Thoreen CC; Kang SA; Chang JW; Liu Q; Zhang J; Gao Y; Reichling LJ; Sim T; Sabatini DM; Gray NS
J Biol Chem; 2009 Mar; 284(12):8023-32. PubMed ID: 19150980
[TBL] [Abstract][Full Text] [Related]
16. New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs).
Feldman ME; Shokat KM
Curr Top Microbiol Immunol; 2010; 347():241-62. PubMed ID: 20549474
[TBL] [Abstract][Full Text] [Related]
17. Defining the role of mTOR pathway in the regulation of stem cells of glioblastoma.
Jhanwar-Uniyal M; Gellerson O; Bree J; Das M; Kleinman G; Gandhi CD
Adv Biol Regul; 2023 May; 88():100946. PubMed ID: 36658088
[TBL] [Abstract][Full Text] [Related]
18. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR.
Chen SM; Liu JL; Wang X; Liang C; Ding J; Meng LH
Biochem Pharmacol; 2012 May; 83(9):1183-94. PubMed ID: 22305748
[TBL] [Abstract][Full Text] [Related]
20. Aberrant CD8+ T-cell responses and memory differentiation upon viral infection of an ataxia-telangiectasia mouse model driven by hyper-activated Akt and mTORC1 signaling.
D'Souza AD; Parish IA; McKay SE; Kaech SM; Shadel GS
Am J Pathol; 2011 Jun; 178(6):2740-51. PubMed ID: 21641396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
